[en] BACKGROUND: Whether vedolizumab may be effective as a treatment for primary sclerosing cholangitis [PSC] in patients with inflammatory bowel disease [IBD] remains controversial. METHODS: We performed a retrospective observational study of consecutive patients with IBD and PSC, treated with vedolizumab for at least 30 weeks in 22 centres of GETAID from January 2015 to June 2016. The outcomes included a decrease in the serum alkaline phosphatase [ALP] concentration of at least 50% from baseline to Week 30 or 54, a change in any serum liver enzymes concentrations, and an assessment of the efficacy and safety of vedolizumab in IBD. RESULTS: Among 75 patients with active IBD and PSC treated with vedolizumab, 21 patients discontinued vedolizumab before Week 30 [due to lack of efficacy in 19 and malignancy in two patients]. In the remaining 54 patients, a decrease in the serum ALP concentration of at least 50% from baseline to Weeks 30 and 54 was observed in four [7%] and four [11%] patients, respectively. No significant change was observed in serum liver enzyme concentrations at week 30 or 54. After a median follow-up period of 19.4 [14.0-29.9] months, nine cases of digestive neoplasia [colorectal neoplasia in seven and cholangiocarcinoma in two] were reported. CONCLUSIONS: In patients with IBD and PSC, vedolizumab did not improve serum liver enzyme concentrations at week 30 or 54. Nine cases of digestive cancer occurred during the follow-up period, confirming the need for a tight surveillance programme in this population.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Caron, Benedicte; Department of Gastroenterology, Hôpitaux Universitaires de Strasbourg [Hôpital de Hautepierre] and INSERM U1113 IRFAC, Université de Strasbourg [Faculté de Médecine], Strasbourg, France.
Peyrin-Biroulet, Laurent; INSERM U954 and Department of Gastroenterology, Université de Lorraine, Nancy, France.
Pariente, Benjamin; Department of Gastroenterology, Huriez Hospital, Université of Lille, Lille, France.
Bouhnik, Yoram; Department of Gastroenterology, IBD and Nutrition Support, Beaujon Hospital, University Paris 7 Denis Diderot, Clichy, France.
Seksik, Philippe; Department of Gastroenterology, AP-HP, Hôpital Saint-Antoine, ERL 1057 INSERM/UMRS 7203, UPMC Université Paris 6, Paris, France.
Bouguen, Guillaume; Department of Gastroenterology, Pontchaillou Hospital and Rennes University, Rennes, France.
Caillo, Ludovic; Department of Gastroenterology, Nimes University Hospital, Nimes, France.
Laharie, David; Department of Hepato-Gastroenterology, University Hospital of Bordeaux, Hôpital Haut-Lévêque, Bordeaux, France.
Carbonnel, Franck; Department of Gastroenterology, Bicetre University Hospital, APHP, Université Paris Sud, le Kremlin Bicêtre, Paris, France.
Altwegg, Romain; Department of Gastroenterology, Hôpital Saint-Eloi, University Hospital of Montpellier, Montpellier, France.
Reenaers, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Serrero, Melanie; Hôpital Nord, Centre d'investigation clinique Marseille Nord, Université Méditerranée, Marseille, France.
Trang-Poisson, Caroline; Department of Gastroenterology, Institut des Maladies de l'appareil Digestif [IMAD], University Hospital of Nantes, Nantes University, Nantes, France.
Nancey, Stephane; Department of Gastroenterology, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Pierre-Benite, France.
Filippi, Jerome; Department of Gastroenterology and Clinical Nutrition, Nice University Hospital, University of Nice Sophia-Antipolis, Nice, France.
Abitbol, Vered; Department of Gastroenterology, Cochin Hospital, University Paris 5 Descartes, Paris, France.
Savoye, Guillaume; Department of Gastroenterology, Rouen University and Hospital, Rouen, France.
Vuitton, Lucine; Department of Gastroenterology, Besançon University Hospital, Besançon, France.
Viennot, Stephanie; Department of Gastroenterology, Caen University Hospital, Caen, France.
Fumery, Mathurin; Department of Gastroenterology, Amiens University Hospital, Amiens, France.
Reymond, Maud; Department of Hepato-Gastroenterology, University Hospital Estaing of Clermont-Ferrand, Université d'Auvergne, Clermont-Ferrand, France.
Bronowicki, Jean-Pierre; INSERM U954 and Department of Gastroenterology, Université de Lorraine, Nancy, France.
Reimund, Jean-Marie; Department of Gastroenterology, Hôpitaux Universitaires de Strasbourg [Hôpital de Hautepierre] and INSERM U1113 IRFAC, Université de Strasbourg [Faculté de Médecine], Strasbourg, France.
Amiot, Aurelien; Department of Gastroenterology, Henri Mondor Hospital, APHP, EC2M3-EA7375, Paris Est-Créteil Val de Marne University, Creteil, France.
Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med 2016;375:1161-70.
Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and infammatory bowel disease. Aliment Pharmacol Ther 2011;34:497-508.
Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study group. N Engl J Med 1997;336:691-5.
Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106:1638-45.
Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-6.
Hillan KJ, Hagler KE, MacSween RN, et al. Expression of the mucosal vascular addressin, MAdCAM-1, in infammatory liver disease. Liver 1999;19:509-18.
Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of infammatory bowel disease. Lancet 2002;359:150-7.
Grant AJ, Lalor PF, Hübscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic infammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium [MAdCAM-1 in chronic infamma-tory liver disease]. Hepatology 2001;33:1065-72.
Eksteen B, Grant AJ, Miles A, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200:1511-7.
Eksteen B, Mora JR, Haughton EL, et al. Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology 2009;137:320-9.
Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507.
Christensen B, Micic D, Gibson PR, et al. Vedolizumab in patients with concurrent primary sclerosing cholangitis and infammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther 2018;47:753-62.
Tse CS, Loftus EV Jr, Raffals LE, Gossard AA, Lightner AL. Effects of vedolizumab, adalimumab and infiximab on biliary infammation in individuals with primary sclerosing cholangitis and infammatory bowel disease. Aliment Pharmacol Ther 2018;48:190-5.
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infiximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of infammatory bowel disease. Aliment Pharmacol Ther 2017;46:3-15.
Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with infammatory bowel disease. J Gastroenterol 2018;53:1048-64.
Boonstra K, Weersma RK, van Erpecum KJ, et al.; EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045-55.
Khaderi SA, Sussman NL. Screening for malignancy in primary sclerosing cholangitis [PSC]. Curr Gastroenterol Rep 2015;17:17.
Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in infammatory bowel disease. Aliment Pharmacol Ther 2015;41:1227-36.
Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017;66:839-51.
